For the quarter ending 2026-03-31, OTLC had -$25,243 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss before non-controlling interests | -2,239,276 | 250,293,099 | -1,114,369 | -153,815 |
| Amortization of debt discount and deferred financing costs | 145,583 | 62,480 | 54,478 | 81,095 |
| Change in fair value of investment in gmp bio | - | 365,346,775 | - | - |
| Deferred income taxes | - | 111,550,000 | - | - |
| Stock compensation expense | 1,641,847 | 2,195,094 | 183,742 | - |
| Loss on debt conversion | - | -1,058,976 | - | 0 |
| Change in fair value of derivative | -90,080 | 320,800 | -392,058 | 424,830 |
| Common shares issued to investors | 130,766 | - | - | - |
| Accounts receivables | -49,266 | - | - | - |
| Prepaid expenses and other current assets | -5,340 | 18,750 | -20,894 | 1,487 |
| Accounts payable and accrued expenses | -166,363 | -256,854 | 155,661 | 204,904 |
| Accounts payable to related party | 514 | 513 | 514 | 1,027 |
| Proceeds from sales of common stock | - | - | - | 0 |
| Net cash used in operating activities | -342,243 | -783,017 | -307,022 | -293,106 |
| Proceeds from convertible debt | 350,000 | 0 | 478,000 | 0 |
| Repaid to note holders | - | - | - | 0 |
| Proceeds from short-term loan, related party | 17,000 | 462,874 | 150,000 | 295,000 |
| Proceeds from / (repayment to) private placement | - | - | - | 0 |
| Repayment of short-term loans, others | 50,000 | - | - | 0 |
| Net cash provided by financing activities | 317,000 | 462,874 | 628,000 | 295,000 |
| Net decrease in cash, cash equivalents and restricted cash | -25,243 | -320,143 | 320,978 | 1,894 |
| Cash, cash equivalents and restricted cash - beginning of period | 108,857 | 429,000 | 106,128 | - |
| Cash, cash equivalents and restricted cash - end of period | 83,614 | 108,857 | 429,000 | - |
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. (OTLC)